Narcolepsy type 1 (NT1) is a lifelong sleep disorder, primarily characterized clinically by excessive daytime sleepiness and cataplexy and pathologically by the loss of hypocretinergic neurons in the lateral hypothalamus. Despite being a rare disorder, the NT1-related burden for patients and society is relevant due to the early onset and chronic nature of this condition. Although the etiology of narcolepsy is still unknown, mounting evidence supports a central role of autoimmunity. To date, no cure is available for this disorder and current treatment is symptomatic. Based on the hypothesis of the autoimmune etiology of this disease, immunotherapy could possibly represent a valid therapeutic option. However, contrasting and limited results have been provided so far. This review discusses the evidence supporting the use of immunotherapy in narcolepsy, the outcomes obtained so far, current issues and future directions.

Giannoccaro M.P., Liguori R., Plazzi G., Pizza F. (2021). Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder. NATURE AND SCIENCE OF SLEEP, 13, 557-577 [10.2147/NSS.S275931].

Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder

Giannoccaro M. P.;Liguori R.;Plazzi G.;Pizza F.
2021

Abstract

Narcolepsy type 1 (NT1) is a lifelong sleep disorder, primarily characterized clinically by excessive daytime sleepiness and cataplexy and pathologically by the loss of hypocretinergic neurons in the lateral hypothalamus. Despite being a rare disorder, the NT1-related burden for patients and society is relevant due to the early onset and chronic nature of this condition. Although the etiology of narcolepsy is still unknown, mounting evidence supports a central role of autoimmunity. To date, no cure is available for this disorder and current treatment is symptomatic. Based on the hypothesis of the autoimmune etiology of this disease, immunotherapy could possibly represent a valid therapeutic option. However, contrasting and limited results have been provided so far. This review discusses the evidence supporting the use of immunotherapy in narcolepsy, the outcomes obtained so far, current issues and future directions.
2021
Giannoccaro M.P., Liguori R., Plazzi G., Pizza F. (2021). Reviewing the clinical implications of treating narcolepsy as an autoimmune disorder. NATURE AND SCIENCE OF SLEEP, 13, 557-577 [10.2147/NSS.S275931].
Giannoccaro M.P.; Liguori R.; Plazzi G.; Pizza F.
File in questo prodotto:
File Dimensione Formato  
NSS-275931-reviewing-the-clinical-implications-of-treating-narcolepsy-a.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 2.4 MB
Formato Adobe PDF
2.4 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/851901
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact